Good Life Advisors’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.83M | Buy |
75,425
+3,170
| +4% | +$73.9K | 0.11% | 153 |
|
|
2025
Q1 | $1.83M | Buy |
72,255
+845
| +1% | +$22.1K | 0.13% | 141 |
|
|
2024
Q4 | $1.89M | Buy |
71,410
+15,211
| +27% | +$413K | 0.14% | 134 |
|
|
2024
Q3 | $1.63M | Buy |
56,199
+3,869
| +7% | +$113K | 0.1% | 162 |
|
|
2024
Q2 | $1.46M | Buy |
52,330
+10,514
| +25% | +$289K | 0.12% | 144 |
|
|
2024
Q1 | $1.16M | Buy |
41,816
+10,192
| +32% | +$283K | 0.1% | 150 |
|
|
2023
Q4 | $910K | Buy |
31,624
+1,468
| +5% | +$44.4K | 0.09% | 167 |
|
|
2023
Q3 | $1M | Buy |
30,156
+376
| +1% | +$13.3K | 0.11% | 153 |
|
|
2023
Q2 | $1.09M | Buy |
29,780
+1,756
| +6% | +$68.3K | 0.12% | 138 |
|
|
2023
Q1 | $1.14M | Sell |
28,024
-1,677
| -6% | -$72.4K | 0.15% | 124 |
|
|
2022
Q4 | $1.52M | Buy |
29,701
+636
| +2% | +$30.5K | 0.21% | 103 |
|
|
2022
Q3 | $1.27M | Sell |
29,065
-104
| -0.4% | -$5.05K | 0.19% | 108 |
|
|
2022
Q2 | $1.53M | Sell |
29,169
-3,277
| -10% | -$167K | 0.21% | 93 |
|
|
2022
Q1 | $1.68M | Buy |
32,446
+583
| +2% | +$30.2K | 0.21% | 93 |
|
|
2021
Q4 | $1.88M | Buy |
31,863
+51
| +0.2% | +$2.53K | 0.23% | 84 |
|
|
2021
Q3 | $1.37M | Buy |
31,812
+1,648
| +5% | +$73K | 0.19% | 97 |
|
|
2021
Q2 | $1.18M | Buy |
30,164
+3,138
| +12% | +$122K | 0.22% | 84 |
|
|
2021
Q1 | $975K | Buy |
27,026
+1,281
| +5% | +$45.5K | 0.2% | 95 |
|
|
2020
Q4 | $947K | Sell |
25,745
-1,502
| -6% | -$55.1K | 0.22% | 82 |
|
|
2020
Q3 | $949K | Buy |
27,247
+2,431
| +10% | +$85.2K | 0.26% | 74 |
|
|
2020
Q2 | $773K | Buy |
24,816
+1,463
| +6% | +$49.7K | 0.23% | 83 |
|
|
2020
Q1 | $724K | Sell |
23,353
-2,565
| -10% | -$87.4K | 0.26% | 84 |
|
|
2019
Q4 | $971K | Buy |
25,918
+776
| +3% | +$27.6K | 0.28% | 71 |
|
|
2019
Q3 | $855K | Sell |
25,142
-760
| -3% | -$27.6K | 0.26% | 73 |
|
|
2019
Q2 | $1.07M | Buy |
25,902
+920
| +4% | +$36.5K | 0.31% | 56 |
|
|
2019
Q1 | $1.01M | Buy |
24,982
+3,061
| +14% | +$123K | 0.3% | 58 |
|
|
2018
Q4 | $908K | Buy |
21,921
+6,786
| +45% | +$282K | 0.29% | 61 |
|
|
2018
Q3 | $633K | Sell |
15,135
-4,730
| -24% | -$182K | 0.18% | 98 |
|
|
2018
Q2 | $679K | Buy |
19,865
+1,112
| +6% | +$38K | 0.22% | 85 |
|
|
2018
Q1 | $625K | Buy |
18,753
+886
| +5% | +$30.5K | 0.21% | 81 |
|
|
2017
Q4 | $619K | Buy |
17,867
+677
| +4% | +$23.1K | 0.19% | 84 |
|
|
2017
Q3 | $588K | Sell |
17,190
-2,121
| -11% | -$68.2K | 0.22% | 74 |
|
|
2017
Q2 | $615K | Sell |
19,311
-28
| -0.1% | -$883 | 0.27% | 69 |
|
|
2017
Q1 | $624K | Buy |
19,339
+3,825
| +25% | +$121K | 0.3% | 61 |
|
|
2016
Q4 | $484K | Buy |
+15,514
| New | +$474K | 0.28% | 62 |
|
Other funds holding PFE
Good Life Advisors's PFE Position: Q2 2025 in Review
Good Life Advisors increased its Pfizer (PFE) stake by 4.4% in Q2 2025, buying an estimated $73.9K and bringing the position to 75,425 shares worth $1.83M. The position accounts for 0.11% of the portfolio, ranked #153.
Good Life Advisors first reported a position in PFE in Q4 2016 and has held it in 35 quarters since. The position peaked at $1.89M in Q4 2024. 2,810 funds tracked by Wall St. Rank hold PFE as of Q2 2025.
- Good Life Advisors held 75,425 shares of Pfizer worth $1.83M as of Q2 2025.
- Good Life Advisors bought 3,170 Pfizer shares in Q2 2025, an estimated $73.9K.
- Pfizer made up 0.11% of Good Life Advisors's portfolio in Q2 2025, its #153 holding.
- Good Life Advisors first reported a position in Pfizer in Q4 2016 and has held it in 35 quarters since.
- Good Life Advisors's Pfizer position peaked at $1.89M in Q4 2024.
- 2,810 funds tracked by Wall St. Rank held Pfizer as of Q2 2025.
Based on Good Life Advisors's 13F filing for Q2 2025, filed 8 Aug 2025.